BR112015024537A2 - terapia de câncer - Google Patents

terapia de câncer

Info

Publication number
BR112015024537A2
BR112015024537A2 BR112015024537A BR112015024537A BR112015024537A2 BR 112015024537 A2 BR112015024537 A2 BR 112015024537A2 BR 112015024537 A BR112015024537 A BR 112015024537A BR 112015024537 A BR112015024537 A BR 112015024537A BR 112015024537 A2 BR112015024537 A2 BR 112015024537A2
Authority
BR
Brazil
Prior art keywords
cancers
cancer therapy
present
therapy
cancer
Prior art date
Application number
BR112015024537A
Other languages
English (en)
Other versions
BR112015024537B1 (pt
BR112015024537A8 (pt
Inventor
Lambert Bent Rebecca
Original Assignee
Lambert Bent Rebecca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lambert Bent Rebecca filed Critical Lambert Bent Rebecca
Publication of BR112015024537A2 publication Critical patent/BR112015024537A2/pt
Publication of BR112015024537A8 publication Critical patent/BR112015024537A8/pt
Publication of BR112015024537B1 publication Critical patent/BR112015024537B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "terapia de câncer". a presente invenção refere-se a composições e métodos para o tratamento de cânceres, especialmente cânceres de origem epitelial. a terapia com uma pluralidade de agentes nutracêuticos, não quimioterapêuticos e quimioterapêuticos, os quais, juntos, objetivam uma pluralidade de processos que dão suporte ao câncer em um paciente, é descrita. dentre outras coisas, a presente invenção abrange o conhecimento de que objetivação redundante de tais vias múltiplas fornece um tratamento eficaz para uma variedade de cânceres, in-cluindo cânceres em estágio terminal, cânceres metastáticos e/ou cânceres que falharam no tratamento com quimioterapia tradicional e/ou outras modalidades terapêuticas.
BR112015024537-4A 2013-04-12 2014-04-11 Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer BR112015024537B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811209P 2013-04-12 2013-04-12
US61/811,209 2013-04-12
PCT/US2014/033820 WO2014169221A2 (en) 2013-04-12 2014-04-11 Cancer therapy

Publications (3)

Publication Number Publication Date
BR112015024537A2 true BR112015024537A2 (pt) 2017-07-18
BR112015024537A8 BR112015024537A8 (pt) 2019-12-10
BR112015024537B1 BR112015024537B1 (pt) 2022-09-06

Family

ID=50771615

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024537-4A BR112015024537B1 (pt) 2013-04-12 2014-04-11 Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer

Country Status (10)

Country Link
US (3) US10195219B2 (pt)
EP (1) EP2983673A2 (pt)
JP (4) JP2016516781A (pt)
CN (3) CN112023054A (pt)
AU (3) AU2014250795B2 (pt)
BR (1) BR112015024537B1 (pt)
CA (1) CA2909349C (pt)
HK (1) HK1220900A1 (pt)
SG (2) SG11201509707QA (pt)
WO (1) WO2014169221A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023054A (zh) 2013-04-12 2020-12-04 内德生物系统有限公司 癌症的治疗
CN112023053A (zh) * 2014-07-17 2020-12-04 益生菌股份公司 治疗对化疗有抗性的肿瘤的组合物及其应用
RU2017132516A (ru) 2015-03-05 2019-04-08 Пробиотикал С.П.А Композиции для применения в лечении опухолей, резистентных к химиотерапии
WO2017216257A1 (en) * 2016-06-15 2017-12-21 Deutsches Krebsforschungszentrum Cancer treatment by simultaneous targeting energy metabolism and intracellular ph
SG10201609131YA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
WO2019071007A1 (en) * 2017-10-05 2019-04-11 New York Genome Center, Inc. METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM
EP3784273A1 (en) * 2018-04-25 2021-03-03 Université catholique de Louvain Combination of metformin and cyclophosphamide as an adjuvant in cancer immunotherapy
WO2020061254A1 (en) * 2018-09-19 2020-03-26 Virginia Tech Intellectual Properties, Inc. Brca1 modulating compounds, formulations thereof, and uses thereof
CN109674990A (zh) * 2019-01-30 2019-04-26 中国人民解放军西部战区总医院 具有调节egfr作用的组合物及其制备方法
KR102347996B1 (ko) * 2020-03-02 2022-01-07 아주대학교산학협력단 메트포르민을 유효성분으로 포함하는 혈관신생 억제용 약학적 조성물
CN111419831B (zh) * 2020-04-08 2021-09-21 温州医科大学 二甲双胍靶向cox6b2在制备治疗胰腺癌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
ATE275959T1 (de) 1992-05-19 2004-10-15 Graham Edmund Kelly Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
WO2001078783A2 (en) 2000-04-17 2001-10-25 Hauser, Inc. Compositions comprising natural agents for treatment of cancer
BRPI1010979A2 (pt) * 2009-05-15 2018-03-06 Novartis Ag "combinação de um inibidor de fosfoinositídeo 3- quinase e de uma composto antidiabético"
AU2010292599A1 (en) * 2009-08-25 2012-03-15 President And Fellows Of Harvard College Use of metformin in cancer treatment and prevention
WO2012075679A1 (en) 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
CN112023054A (zh) 2013-04-12 2020-12-04 内德生物系统有限公司 癌症的治疗

Also Published As

Publication number Publication date
WO2014169221A3 (en) 2015-01-15
JP6870046B2 (ja) 2021-05-12
BR112015024537B1 (pt) 2022-09-06
AU2019236645A1 (en) 2019-10-17
US20160030454A1 (en) 2016-02-04
US11083740B2 (en) 2021-08-10
JP6757360B2 (ja) 2020-09-16
JP2021001234A (ja) 2021-01-07
CN112023054A (zh) 2020-12-04
SG10201913730RA (en) 2020-03-30
US10195219B2 (en) 2019-02-05
CN105120876A (zh) 2015-12-02
AU2019236645B2 (en) 2022-02-03
HK1220900A1 (zh) 2017-05-19
AU2014250795A1 (en) 2015-09-03
SG11201509707QA (en) 2015-12-30
AU2014250795B2 (en) 2019-07-18
JP2018119013A (ja) 2018-08-02
EP2983673A2 (en) 2016-02-17
AU2022202814A1 (en) 2022-05-19
CA2909349A1 (en) 2014-10-16
BR112015024537A8 (pt) 2019-12-10
AU2019236645B9 (en) 2022-06-02
US20190175626A1 (en) 2019-06-13
CA2909349C (en) 2023-01-03
CN112022853A (zh) 2020-12-04
US20220168324A1 (en) 2022-06-02
JP2016516781A (ja) 2016-06-09
JP2019203034A (ja) 2019-11-28
WO2014169221A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
BR112015024537A2 (pt) terapia de câncer
BR112017023269A2 (pt) métodos para tratamento de câncer
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
BR112017020780A2 (pt) métodos de administração de inibidores de glutaminase
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
BR112018073786A2 (pt) métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk
NZ722326A (en) Tricyclic compounds as anticancer agents
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
MX366623B (es) 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas.
BR112015030389A2 (pt) uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
MX2017015896A (es) Agente anticancerigeno.
BR112017008045A2 (pt) compostos como inibidores de nik
BR112016025764A2 (pt) vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
BR112015026292A2 (pt) tratamento de câncer com dihidropirazino-pirazinas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UMA PARECER DE EXIGENCIA NOTIFICADO NA RPI NO 2672, DE 22/03/22, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECAO EM RELACAO AO COMENTARIO DA REIVINDICACAO 10 DO QUADRO REIVINDICATORIO PETICAO DE NO 870210115421 DE 15.12.2021, ASSIM REPUBLICO A REFERIDA PUBLICACAO.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2014, OBSERVADAS AS CONDICOES LEGAIS